{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:18:29Z","timestamp":1783160309159,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2024J408"],"award-info":[{"award-number":["2024J408"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2022J021"],"award-info":[{"award-number":["2022J021"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.prp.2026.156477","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:09:07Z","timestamp":1776701347000},"page":"156477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-3155","authenticated-orcid":false,"given":"Haifen","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zining","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7161-5507","authenticated-orcid":false,"given":"Junqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.prp.2026.156477_bib1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.7150\/jca.36927","article-title":"Thirty-year trends in clinicopathologic characteristics and prognosis after gastrectomy for gastric cancer: a single institution in Northern China","volume":"11","author":"Tan","year":"2020","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.prp.2026.156477_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/15384101.2020.1731945","article-title":"Oncogenic hsa_circ_0091581 promotes the malignancy of HCC cell through blocking miR-526b from degrading c-MYC mRNA","volume":"19","author":"Wei","year":"2020","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.prp.2026.156477_bib4","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.prp.2018.07.037","volume":"214","author":"Zhao","year":"2018","journal-title":"Pathol. Res. Pr."},{"issue":"3","key":"10.1016\/j.prp.2026.156477_bib5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s10637-025-01530-x","article-title":"Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells","volume":"43","author":"Zhou","year":"2025","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.prp.2026.156477_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pccm.2025.08.005","article-title":"Chimeric antigen receptor-T cell therapy for lung cancer: the tumor microenvironment bottleneck and remedies to circumvent it","volume":"3","author":"Zhou","year":"2025","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"10.1016\/j.prp.2026.156477_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100391","article-title":"Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target","volume":"30","author":"Nie","year":"2021","journal-title":"J. Bone Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156477_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/153537020122600503","article-title":"Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants","volume":"226","author":"Mizejewski","year":"2001","journal-title":"Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156477_bib9","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.3892\/ol.2017.6514","article-title":"Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: a case report","volume":"14","author":"Arakawa","year":"2017","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.prp.2026.156477_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2559.2006.02522.x","article-title":"Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma","volume":"49","author":"Hishinuma","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2026.156477_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2019.00248","article-title":"Next-generation cancer immunotherapy targeting glypican-3","volume":"9","author":"Shimizu","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2026.156477_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.matbio.2013.12.007","article-title":"The role of glypicans in Hedgehog signaling","volume":"35","author":"Filmus","year":"2014","journal-title":"Matrix Biol."},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/med.21455","article-title":"Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.prp.2026.156477_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3389\/fonc.2019.00708","article-title":"The role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer","volume":"9","author":"Kolluri","year":"2019","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156477_bib15","first-page":"807","article-title":"Frequent silencing of the GPC3 gene in ovarian cancer cell lines","volume":"59","author":"Lin","year":"1999","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00063030-200519020-00001","article-title":"Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma","volume":"19","author":"Nakatsura","year":"2005","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.prp.2026.156477_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s12672-024-01694-7","article-title":"Identification of gastric cancer subtypes based on disulfidptosis-related genes: GPC3 as a novel biomarker for prognosis prediction","volume":"15","author":"Yi","year":"2024","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156477_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2189295","article-title":"Targeting GPC3high cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer","volume":"55","author":"Li","year":"2023","journal-title":"Ann. Med."},{"issue":"4","key":"10.1016\/j.prp.2026.156477_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3727\/096504016X14768374457986","article-title":"MicroRNA-219-5p Represses the proliferation, migration, and invasion of gastric cancer cells by targeting the LRH-1\/Wnt\/\u03b2-catenin signaling pathway","volume":"25","author":"Li","year":"2017","journal-title":"Oncol. Res"},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10585-021-10143-6","article-title":"Identification of miR-4510 as a metastasis suppressor of gastric cancer through regulation of tumor microenvironment via targeting GPC3","volume":"39","author":"Ma","year":"2022","journal-title":"Clin. Exp. Metastas."},{"issue":"4","key":"10.1016\/j.prp.2026.156477_bib21","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1349-7006.2009.01108.x","article-title":"Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas","volume":"100","author":"Ushiku","year":"2009","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.prp.2026.156477_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/PAS.0000000000000869","article-title":"Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma","volume":"41","author":"Yamazawa","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2026.156477_bib23","article-title":"Clinicopathological significance of identifying glypican 3 -positive gastric cancer","volume":"272","author":"Ma","year":"2025","journal-title":"Pathol. Res Pr."},{"issue":"28","key":"10.1016\/j.prp.2026.156477_bib24","doi-asserted-by":"crossref","first-page":"44406","DOI":"10.18632\/oncotarget.9763","article-title":"Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.prp.2026.156477_bib25","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1309\/HCQWPWD50XHD2DW6","article-title":"Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples","volume":"129","author":"Baumhoer","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2026.156477_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/PAS.0b013e31823aafec","article-title":"Histologic and immunohistochemical analyses of \u03b1-fetoprotein--producing cancer of the stomach","volume":"36","author":"Kinjo","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.prp.2026.156477_bib27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.humpath.2014.02.003","article-title":"Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma","volume":"45","author":"Osada","year":"2014","journal-title":"Hum. Pathol."},{"issue":"36","key":"10.1016\/j.prp.2026.156477_bib28","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.3748\/wjg.v22.i36.8203","article-title":"Clinicopathological features of alpha-fetoprotein producing early gastric cancer with enteroblastic differentiation","volume":"22","author":"Matsumoto","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10120-015-0497-9","article-title":"Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases","volume":"19","author":"Murakami","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prp.2026.156477_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humpath.2018.04.022","article-title":"Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma","volume":"78","author":"Akazawa","year":"2018","journal-title":"Hum. Pathol."},{"issue":"7","key":"10.1016\/j.prp.2026.156477_bib31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jclinpath-2017-204928","article-title":"HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types","volume":"71","author":"Fujimoto","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5114\/pjp.2018.76696","article-title":"Clinicopathologic study of 10 cases of gastric adenocarcinoma with hepatoid or enteroblastic differentiation","volume":"69","author":"Kuroda","year":"2018","journal-title":"Pol. J. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2026.156477_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/jclinpath-2017-204535","article-title":"Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis","volume":"71","author":"Arora","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"9","key":"10.1016\/j.prp.2026.156477_bib34","article-title":"Gastric adenocarcinoma with enteroblastic differentiation should be differentiated from hepatoid adenocarcinoma: a study with emphasis on clear cells and clinicopathologic spectrum","volume":"215","author":"Kwon","year":"2019","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2026.156477_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.humpath.2021.02.003","article-title":"Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers","volume":"115","author":"He","year":"2021","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2026.156477_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12876-021-01986-0","article-title":"Both the serum AFP test and AFP\/GPC3\/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Gastroenterol."},{"issue":"9","key":"10.1016\/j.prp.2026.156477_bib37","first-page":"886","article-title":"Gastric adenocarcinoma with enteroblastic differentiation and elevated serum alpha fetoprotein","volume":"49","author":"Li","year":"2020","journal-title":"Zhonghua Bing. Li Xue Za Zhi"},{"issue":"6","key":"10.1016\/j.prp.2026.156477_bib38","first-page":"626","article-title":"Clinicopathological features of gastric adenocarcinoma with enteroblastic differentiation: a report of twelve cases","volume":"50","author":"Li","year":"2021","journal-title":"Zhonghua Bing. Li Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.prp.2026.156477_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13000-021-01128-w","article-title":"Clinicopathological significance of primitive phenotypes in early gastric cancer with differentiated histology","volume":"16","author":"Zhou","year":"2021","journal-title":"Diagn. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2026.156477_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00428-023-03623-5","article-title":"Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression","volume":"483","author":"Abe","year":"2023","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.prp.2026.156477_bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/his.14998","article-title":"Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation","volume":"83","author":"Wang","year":"2023","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.prp.2026.156477_bib42","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.62347\/RRHG4189","article-title":"Gastric adenocarcinoma with intestinal progenitor cell differentiation: a morphologically underdiagnosed and more invasive distinctive type of gastric adenocarcinoma","volume":"14","author":"Ge","year":"2024","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.prp.2026.156477_bib43","first-page":"686","article-title":"Clinicopathological analysis of gastric adenocarcinoma with elevated serum alpha-fetoprotein and enteroblastic differentiation","volume":"46","author":"Zan","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"3","key":"10.1016\/j.prp.2026.156477_bib44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s10120-025-01594-x","article-title":"Genomic landscape and potential therapeutic targets in alpha-fetoprotein-producing gastric cancer","volume":"28","author":"Zan","year":"2025","journal-title":"Gastric Cancer"},{"issue":"7","key":"10.1016\/j.prp.2026.156477_bib45","first-page":"748","article-title":"Characteristics of gastric hepatoid adenocarcinoma: a clinicopathological and molecular analysis","volume":"54","author":"Wang","year":"2025","journal-title":"Zhonghua Bing. Li Xue Za Zhi"},{"key":"10.1016\/j.prp.2026.156477_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2025.102325","article-title":"Molecular profiling of hepatoid adenocarcinoma and adenocarcinoma with enteroblastic differentiation","volume":"64","author":"Matsumoto","year":"2026","journal-title":"Surg. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156477_bib47","first-page":"6762","article-title":"Hepatoid adenocarcinoma of the stomach is a special and easily misdiagnosed or missed diagnosed subtype of gastric cancer with poor prognosis but curative for patients of pN0\/1: the experience of a single center","volume":"8","author":"Xie","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156477_bib48","first-page":"321","article-title":"Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers","volume":"87","author":"Chang","year":"1992","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.prp.2026.156477_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000065838","article-title":"Clinicopathologic features of gastric cancers producing alpha-fetoprotein","volume":"19","author":"Kono","year":"2002","journal-title":"Dig. Surg."},{"issue":"6","key":"10.1016\/j.prp.2026.156477_bib50","first-page":"805","article-title":"[Two cases of gastric cancer expressing Glypican 3, but producing AFP with different lectin affinity]","volume":"106","author":"Oishi","year":"2009","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.prp.2026.156477_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1267186","article-title":"Comprehensive multi-omics analysis of tryptophan metabolism-related gene expression signature to predict prognosis in gastric cancer","volume":"14","author":"Luo","year":"2023","journal-title":"Front Pharm."},{"issue":"4","key":"10.1016\/j.prp.2026.156477_bib52","first-page":"2657","article-title":"Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery","volume":"19","author":"Miura","year":"2020","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.prp.2026.156477_bib53","first-page":"665","article-title":"Targeting Glypican-3 for liver cancer therapy: clinical applications and detection methods","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.prp.2026.156477_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/5532617","article-title":"GPC3 promotes lung squamous cell carcinoma progression and HLA-A2-restricted GPC3 Antigenic Peptide-Modified Dendritic Cell-Induced Cytotoxic T Lymphocytes to Kill Lung Squamous Cell Carcinoma Cells","volume":"2023","author":"Ning","year":"2023","journal-title":"J. Immunol. Res."},{"issue":"20","key":"10.1016\/j.prp.2026.156477_bib55","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/cancers14205018","article-title":"Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma","volume":"14","author":"Shen","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.prp.2026.156477_bib56","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cac2.12472","article-title":"Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy","volume":"43","author":"Shi","year":"2023","journal-title":"Cancer Commun."},{"issue":"16","key":"10.1016\/j.prp.2026.156477_bib57","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2024.42.16_suppl.4019","article-title":"Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib58","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.prp.2026.156477_bib59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbrc.2008.11.033","article-title":"Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells","volume":"378","author":"Nakano","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.prp.2026.156477_bib60","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10120-025-01647-1","article-title":"Assessing efficacy of anti-glypican-1 antibody-drug conjugate as potential therapeutic approach for gastric cancer","volume":"28","author":"Suzuki","year":"2025","journal-title":"Gastric Cancer"},{"issue":"10294","key":"10.1016\/j.prp.2026.156477_bib61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prp.2026.156477_bib62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/2326-6066.CIR-19-0210","article-title":"XCL1\/Glypican-3 fusion gene immunization generates potent antitumor cellular immunity and enhances anti-PD-1 efficacy","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2026.156477_bib63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40792-023-01653-4","article-title":"Long-term survival with nivolumab followed by irinotecan after total gastrectomy in alpha-fetoprotein-producing gastric cancer: a case report and review of the literature","volume":"9","author":"Ota","year":"2023","journal-title":"Surg. Case Rep."},{"key":"10.1016\/j.prp.2026.156477_bib64","article-title":"Research progress of drugs targeting GPC3 in cancer therapy","volume":"169","author":"Li","year":"2025","journal-title":"Bioorg. Chem."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:50:30Z","timestamp":1783158630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":64,"alternative-id":["S0344033826001305"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156477","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156477"}}